We are live on
!
Find out more
BCM
Burrage Capital Management Portfolio holdings
AUM
$99.7M
1-Year Est. Return
66.05%
This Fund
S&P 500
This Quarter
Est. Return
+11.93%
1 Year Est. Return
+66.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$123M
AUM Growth
-$7.8M
(-5.9%)
Cap. Flow
-$9.25M
Cap. Flow
% of AUM
-7.49%
Top 10 Holdings %
Top 10 Hldgs %
57.11%
Holding
32
New
7
Increased
5
Reduced
13
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EPIX
ESSA Pharma
EPIX
|
+$5.52M |
| 2 |
Harmony Biosciences
HRMY
|
+$5.26M |
| 3 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
+$4.14M |
| 4 |
TVRD
Tvardi Therapeutics
TVRD
|
+$3.42M |
| 5 |
Geron
GERN
|
+$3.42M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$9.59M |
| 2 |
Insmed
INSM
|
+$5.14M |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
+$4.65M |
| 4 |
Korro Bio
KRRO
|
+$4.39M |
| 5 |
EPZM
Epizyme, Inc
EPZM
|
+$3.79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Protalix BioTherapeutics
PLX
$192M
| $9.48M | 7.68% |
2,125,585
-344,747
| -14% | -$1.61M |
|
2
BioCryst Pharmaceuticals
BCRX
$2.36B
| $8.8M | 7.13% |
864,916
-240,757
| -22% | -$2.48M |
|
|
LITS
3
Lite Strategy Inc
LITS
$35M
| $8M | 6.48% |
116,566
-43,731
| -27% | -$3.06M |
|
4
PTC Therapeutics
PTCT
$6.49B
| $7.59M | 6.15% |
160,372
-711
| -0.4% | -$42.2K |
|
5
NeoGenomics
NEO
$1.89B
| $7.13M | 5.78% |
147,921
-30,856
| -17% | -$1.61M |
|
|
EPIX
6
DELISTED
ESSA Pharma
EPIX
| $6.9M | 5.59% |
+237,442
| New | +$5.52M |
|
|
TPTX
7
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $6.83M | 5.53% |
72,164
-320
| -0.4% | -$38.1K |
|
8
Cytokinetics
CYTK
$10.9B
| $5.69M | 4.61% |
244,673
-1,363
| -0.6% | -$29.1K |
|
9
Intellia Therapeutics
NTLA
$1.56B
| $5.11M | 4.14% |
63,634
-445
| -0.7% | -$29.9K |
|
|
10
Harmony Biosciences
HRMY
$1.94B
| $4.96M | 4.02% |
+150,000
| New | +$5.26M |
|
|
EPZM
11
DELISTED
Epizyme, Inc
EPZM
| $4.92M | 3.98% |
564,555
-365,912
| -39% | -$3.79M |
|
12
Crinetics Pharmaceuticals
CRNX
$8.88B
| $4.16M | 3.37% |
272,393
+48,264
| +22% | +$748K |
|
13
Mirum Pharmaceuticals
MIRM
$7.14B
| $4.08M | 3.31% |
205,866
+44,238
| +27% | +$847K |
|
|
TVRD
14
Tvardi Therapeutics
TVRD
$28.7M
| $3.91M | 3.17% |
+5,000
| New | +$3.42M |
|
15
Fulcrum Therapeutics
FULC
$245M
| $3.77M | 3.05% |
319,819
+47,893
| +18% | +$592K |
|
|
TCDA
16
DELISTED
Tricida, Inc. Common Stock
TCDA
| $3.48M | 2.82% |
+658,877
| New | +$4.14M |
|
|
APLS
17
DELISTED
Apellis Pharmaceuticals
APLS
| $3.46M | 2.81% |
80,727
-630
| -0.8% | -$29.8K |
|
|
YMAB
18
DELISTED
Y-mAbs Therapeutics
YMAB
| $3.46M | 2.8% |
114,454
-508
| -0.4% | -$20.8K |
|
|
INZY
19
DELISTED
Inozyme Pharma
INZY
| $3.36M | 2.72% |
169,473
-1,323
| -0.8% | -$29.2K |
|
|
TECX
20
Tectonic Therapeutic
TECX
$624M
| $3.11M | 2.52% |
20,410
+8,267
| +68% | +$1.34M |
|
21
ADC Therapeutics
ADCT
$164M
| $3.05M | 2.47% |
124,875
-975
| -0.8% | -$28.2K |
|
|
22
Geron
GERN
$930M
| $3.02M | 2.45% |
+1,912,673
| New | +$3.42M |
|
|
GTHX
23
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $2.83M | 2.29% |
117,708
| – | – |
|
|
MRUS
24
DELISTED
Merus
MRUS
| $2.73M | 2.21% |
130,683
| – | – |
|
25
Black Diamond Therapeutics
BDTX
$103M
| $2.68M | 2.17% |
110,447
+75,556
| +217% | +$2.04M |
|
Similar funds
WCM
CCM
RGM
TCM
RC
AC
QVT
WFWM
Burrage Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Burrage Capital Management held 32 positions worth $123M, down 5.9% from $131M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Burrage Capital Management withdrew a net $9.25M in Q1 2021, closing 5 positions and reducing 13 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $9.59M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.
Against the trend, Burrage Capital Management opened a new position in ESSA Pharma worth $6.9M.
- Burrage Capital Management's largest Q1 2021 buy was ESSA Pharma: 237,442 shares worth $6.9M.
- Burrage Capital Management added most to Black Diamond Therapeutics in Q1 2021, an estimated $2.04M increase.
- Burrage Capital Management's biggest Q1 2021 reduction was Epizyme, Inc, cutting an estimated $3.79M.
- Burrage Capital Management fully exited IVERIC bio, Inc. Common Stock in Q1 2021, selling an estimated $9.59M.
- Burrage Capital Management's ten largest holdings make up 57% of its $123M portfolio in Q1 2021.
- Burrage Capital Management opened 7 new positions and closed 5 in Q1 2021.
- Burrage Capital Management's portfolio value fell 5.9% quarter-over-quarter to $123M.
Based on Burrage Capital Management's 13F filing for Q1 2021, filed 17 May 2021.